BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16472566)

  • 1. Uterine perforation in women using a levonorgestrel-releasing intrauterine system.
    Van Houdenhoven K; van Kaam KJ; van Grootheest AC; Salemans TH; Dunselman GA
    Contraception; 2006 Mar; 73(3):257-60. PubMed ID: 16472566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
    de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
    Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study.
    Kaislasuo J; Suhonen S; Gissler M; Lähteenmäki P; Heikinheimo O
    Hum Reprod; 2012 Sep; 27(9):2658-63. PubMed ID: 22763376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of levonorgestrel-releasing intrauterine system (LNG-IUS) uterine perforation.
    Margarit LM; Griffiths AN; Vine SJ
    J Obstet Gynaecol; 2004 Aug; 24(5):586-7. PubMed ID: 15369954
    [No Abstract]   [Full Text] [Related]  

  • 7. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study.
    Barnett C; Moehner S; Do Minh T; Heinemann K
    Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):424-428. PubMed ID: 29322856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.
    Sheng J; Zhang WY; Zhang JP; Lu D
    Contraception; 2009 Mar; 79(3):189-93. PubMed ID: 19185671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
    Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
    Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levonorgestrel-releasing intrauterine device and uterine perforations.
    Prescrire Int; 2007 Dec; 16(92):248-9. PubMed ID: 18092420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients.
    Trinh XB; Tjalma WA; Makar AP; Buytaert G; Weyler J; van Dam PA
    Fertil Steril; 2008 Jul; 90(1):17-22. PubMed ID: 17706209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding.
    Wildemeersch D; Andrade A
    Gynecol Endocrinol; 2010 May; 26(5):383-9. PubMed ID: 20192899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
    Wildemeersch D; Janssens D; Vrijens M; Weyers S
    Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subject and clinician experience with the levonorgestrel-releasing intrauterine system.
    Jensen JT; Nelson AL; Costales AC
    Contraception; 2008 Jan; 77(1):22-9. PubMed ID: 18082662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy.
    Vilos GA; Tureanu V; Garcia M; Abu-Rafea B
    J Minim Invasive Gynecol; 2009; 16(4):480-4. PubMed ID: 19573825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The levonorgestrel intrauterine system in nulliparous women.
    Prager S; Darney PD
    Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
    Lukes AS; Reardon B; Arepally G
    Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of a perforated levonorgestrel-medicated intrauterine device--a pharmacokinetic study: case report.
    Haimov-Kochman R; Amsalem H; Adoni A; Lavy Y; Spitz IM
    Hum Reprod; 2003 Jun; 18(6):1231-3. PubMed ID: 12773451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical perforation by the strings of a levonorgestrel releasing-intrauterine system: a case report.
    Gönenç I; Vural EZ; Aka N
    Eur J Contracept Reprod Health Care; 2013 Oct; 18(5):415-8. PubMed ID: 23937289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of levonorgestrel - IUD in the treatment of uterine myoma in Thai women.
    Jindabanjerd K; Taneepanichskul S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S147-51. PubMed ID: 17726816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.